Xeris Reports Topline Results From Its Recently Completed Phase 2 Open Label, Study Of XP-8121 For Treatment Of Adults With Hypothyroidism

Participants who completed the study rated higher treatment satisfaction with XP-8121 compared to oral and a majority (72%) indicated a strong preference for the SC route of administration.

Study exposed the challenges of achieving and maintaining normal TSH with daily oral levothyroxine therapy.

FDA End-of-Phase 2 interaction to facilitate a Phase 3 pivotal study program is expected by year-end